Dr. Arnason is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
330 Brookline Ave
Boston, MA 02215Phone+1 617-667-9920Fax+1 617-667-9922- Is this information wrong?
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2007 - 2010
NYU Grossman School of MedicineResidency, Internal Medicine, 2004 - 2007
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2004
Certifications & Licensure
MA State Medical License 2010 - 2025
NY State Medical License 2007 - 2011
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL Start of enrollment: 2010 Jul 01
- Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma Start of enrollment: 2012 Mar 01
- Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL Start of enrollment: 2020 Oct 19
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following fail...Jeremy S Abramson, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernande...> ;Future Oncology. 2024 Mar 28
- Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.Ahn, I., Brander, D., Ren, Y., Zhou, Y., Tyekucheva, S., Walker, H., Black, R., Montegaard, J., Alencar, A., Shune, L., Omaira, M., Jacobson, C., Armand, P., Ng, S., C...> ;Blood Advances. 2024 Feb 27
- 2 citationsTwo-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.Jeremy S Abramson, M Lia Palomba, Leo I Gordon, Matthew Lunning, Michael Wang, Jon Arnason, Enkhtsetseg Purev, David G Maloney, Charalambos Andreadis, Alison Sehgal, S...> ;Blood. 2024 Feb 1
- Join now to see all
Abstracts/Posters
- Development of Novel Second Generation DC/Tumor Fusion Vaccine in LymphomaJon E. Arnason, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLLA Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or R...Jon E. Arnason, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- The Risk of Bleeding in Patients Receiving Ibrutinib Combined with Novel Direct Oral AnticoagulantsJon E. Arnason, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
Tandem Meetings 2023: Research Shows Favorable Results for Lymphoma SubtypesMarch 31st, 2023- Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA to Predict Long-Term OutcomesDecember 13th, 2023
Hospital Affiliations
Beth Israel Deaconess Medical CenterBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
